ZA963907B - Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof - Google Patents

Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof

Info

Publication number
ZA963907B
ZA963907B ZA963907A ZA963907A ZA963907B ZA 963907 B ZA963907 B ZA 963907B ZA 963907 A ZA963907 A ZA 963907A ZA 963907 A ZA963907 A ZA 963907A ZA 963907 B ZA963907 B ZA 963907B
Authority
ZA
South Africa
Prior art keywords
nucleic acid
acid molecules
mhc molecule
form complexes
molecule hla
Prior art date
Application number
ZA963907A
Other languages
English (en)
Inventor
Yannick Guilloux
Franchine Jotereau
Thierry Boon-Falleur
Sophie Lucas
Vincent Brichard
Original Assignee
Ludwig Inst Cancer Res
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Inst Nat Sante Rech Med filed Critical Ludwig Inst Cancer Res
Publication of ZA963907B publication Critical patent/ZA963907B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA963907A 1995-06-07 1996-05-16 Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof ZA963907B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,135 US5821122A (en) 1995-06-07 1995-06-07 Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof

Publications (1)

Publication Number Publication Date
ZA963907B true ZA963907B (en) 1997-03-11

Family

ID=23934549

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA963907A ZA963907B (en) 1995-06-07 1996-05-16 Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof

Country Status (12)

Country Link
US (3) US5821122A (fr)
EP (1) EP0845032B1 (fr)
JP (1) JP3849102B2 (fr)
AT (1) ATE209680T1 (fr)
AU (1) AU704934B2 (fr)
CA (1) CA2223694C (fr)
DE (1) DE69617440T2 (fr)
DK (1) DK0845032T3 (fr)
ES (1) ES2167561T3 (fr)
PT (1) PT845032E (fr)
WO (1) WO1996040039A2 (fr)
ZA (1) ZA963907B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE402259T1 (de) 1997-01-27 2008-08-15 Ludwig Inst Cancer Res Lage-1 tumor-assozierte nukleinsäuren
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US20020164654A1 (en) * 2000-01-20 2002-11-07 Rosalie Luiten MAGE antigenic peptides which bind HLA-B35 and HLA-B44
EP1188446B1 (fr) 2000-09-15 2009-08-05 Institut Pasteur Vecteurs de matériaux protéiniques pour le transport de molécules vers les cellules exprimant le CD11b
JP2004525620A (ja) 2001-01-17 2004-08-26 トルビオン・ファーマシューティカルズ・インコーポレイテッド 結合ドメイン−免疫グロブリン融合タンパク質
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6607151B2 (en) * 2001-08-16 2003-08-19 Morris Samelson Ultra fine dead sea mineral compound and method of manufacture
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
US20070026022A1 (en) * 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
DE602004024440D1 (de) * 2003-11-21 2010-01-14 Pasteur Institut Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
KR20100092031A (ko) * 2004-06-17 2010-08-19 맨카인드 코포레이션 에피토프 유사체
US8188243B2 (en) * 2004-06-23 2012-05-29 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
WO2010080909A1 (fr) 2009-01-08 2010-07-15 Yale University Compositions et procédés d'utilisation de virus de la stomatite vésiculaire à action oncolytique
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (fr) 2009-11-04 2011-05-12 Yale University Compositions et procédés destinés à traiter le cancer par des virus oncolytiques atténués
CA2876209A1 (fr) 2012-06-15 2013-12-19 Adaptive Biotechnologies Corporation Genes de recepteur immunitaire adaptatif reorganises a marquage unique dans un ensemble genique complexe
SG10201707394PA (en) 2013-03-15 2017-10-30 Adaptive Biotechnologies Corp Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
WO2015058111A1 (fr) 2013-10-17 2015-04-23 The Brigham And Women's Hospital, Inc. Nanoparticules cationiques pour co-administration d'acides nucléiques et d'agents thérapeutiques
EP3721875B1 (fr) 2014-05-09 2023-11-08 Yale University Particules revêtues de polyglycérol hyperramifié et leurs procédés de fabrication
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (fr) 2015-12-02 2017-06-08 Partikula Llc Compositions et procédés de modulation du métabolisme de cellules cancéreuses
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3512563A1 (fr) 2016-09-16 2019-07-24 The Johns Hopkins University Nanocages protéiques à pénétration de mucus améliorée pour administration tissulaire et intracellulaire ciblée
US20200085758A1 (en) 2016-12-16 2020-03-19 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
EP3615052B1 (fr) 2017-04-27 2023-01-25 The University of Hong Kong Utilisation d'inhibiteurs de hcn pour le traitement du cancer
US11478433B2 (en) 2017-06-23 2022-10-25 Yale University Nanomaterials with enhanced drug delivery efficiency
WO2023010060A2 (fr) 2021-07-27 2023-02-02 Novab, Inc. Anticorps anti-vlrb génétiquement modifiés présentant des fonctions effectrices immunitaires
WO2023108076A1 (fr) 2021-12-08 2023-06-15 Yale University Conjugaison de surface à des nanoparticules de poly(amine-co-ester) destinées à cibler des cellules et des tissus
WO2023147552A1 (fr) 2022-01-28 2023-08-03 University Of Georgia Research Foundation, Inc. Compositions radiosensibilisantes et leurs procédés d'utilisation
WO2024050524A1 (fr) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions et procédés de direction de l'apolipoprotéine l1 en vue d'induire la mort de cellules de mammifère
WO2024112867A1 (fr) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions et méthodes d'utilisation de celles-ci pour augmenter les réponses immunitaires

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ES2172287T4 (es) * 1992-12-22 2003-04-16 Ludwig Inst Cancer Res Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa.
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules

Also Published As

Publication number Publication date
US5821122A (en) 1998-10-13
PT845032E (pt) 2002-05-31
JP2001520506A (ja) 2001-10-30
US5886145A (en) 1999-03-23
DE69617440T2 (de) 2002-08-08
EP0845032A4 (fr) 2000-05-10
CA2223694A1 (fr) 1996-12-19
AU5676996A (en) 1996-12-30
US5958711A (en) 1999-09-28
DE69617440D1 (de) 2002-01-10
ATE209680T1 (de) 2001-12-15
ES2167561T3 (es) 2002-05-16
WO1996040039A3 (fr) 2000-03-23
AU704934B2 (en) 1999-05-06
EP0845032A2 (fr) 1998-06-03
JP3849102B2 (ja) 2006-11-22
DK0845032T3 (da) 2002-05-06
EP0845032B1 (fr) 2001-11-28
CA2223694C (fr) 2003-06-24
WO1996040039A2 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
ZA963907B (en) Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof
ZA944196B (en) Isolated peptides which form complexes with MHC molecule HLA-C-clone 10 and uses thereof
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
DE69933998D1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
EP0690915A4 (fr) Molecules d'acide nucleique isolees codant le precurseur de l'antigene anti-tumoral mage-3 et leurs utilisations
FI960268A (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
ZA983488B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursors mage-c1 and mage-c2 and uses thereof
CA2213001A1 (fr) Molecule isolee d'acide nucleique codant des peptides formant des complexes avec hla-cw*1601 de la molecule du cmh, et ses utilisations
CA2165435A1 (fr) Nouveaux precurseurs d'antigenes pour le rejet des tumeurs et molecules d'acides nucleiques codant pour ces precurseurs
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
UA66753C2 (en) Immunostimulator and method for its production